These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 16751263)

  • 1. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.
    Meno-Tetang GM; Li H; Mis S; Pyszczynski N; Heining P; Lowe P; Jusko WJ
    Drug Metab Dispos; 2006 Sep; 34(9):1480-7. PubMed ID: 16751263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
    Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
    J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
    Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
    J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
    Skerjanec A; Tedesco H; Neumayer HH; Cole E; Budde K; Hsu CH; Schmouder R
    J Clin Pharmacol; 2005 Nov; 45(11):1268-78. PubMed ID: 16239360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
    Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL
    Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
    Morris MA; Gibb DR; Picard F; Brinkmann V; Straume M; Ley K
    Eur J Immunol; 2005 Dec; 35(12):3570-80. PubMed ID: 16285007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses.
    Li H; Meno-Tetang GM; Chiba K; Arima N; Heining P; Jusko WJ
    J Pharmacol Exp Ther; 2002 May; 301(2):519-26. PubMed ID: 11961052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats.
    Krishnan K; Crouse LC; Bazar MA; Major MA; Reddy G
    J Appl Toxicol; 2009 Oct; 29(7):629-37. PubMed ID: 19629953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
    Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
    Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
    Kovarik JM; Schmouder R; Barilla D; Wang Y; Kraus G
    Br J Clin Pharmacol; 2004 May; 57(5):586-91. PubMed ID: 15089811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
    Sensken SC; Bode C; Gräler MH
    J Pharmacol Exp Ther; 2009 Mar; 328(3):963-9. PubMed ID: 19074680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.
    Meno-Tetang GM; Lowe PJ
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):182-92. PubMed ID: 15733213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FTY720: early clinical experience.
    Dragun D; Fritsche L; Boehler T; Peters H; Budde K; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):544S-548S. PubMed ID: 15041403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
    Kovarik JM; Schmouder RL; Barilla D; Büche M; Rouilly M; Berthier S; Wang Y; Van Saders C; Mayer T; Gottlieb AB
    Ann Pharmacother; 2004; 38(7-8):1153-8. PubMed ID: 15138297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of fingolimod phosphate in healthy participants.
    Wu K; Mercier F; David OJ; Schmouder RL; Looby M
    J Clin Pharmacol; 2012 Jul; 52(7):1054-68. PubMed ID: 22110161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
    Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L
    Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats.
    Schaier M; Vorwalder S; Sommerer C; Dikow R; Hug F; Gross ML; Waldherr R; Zeier M
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F769-80. PubMed ID: 19535570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunomodulator FTY720 is phosphorylated and released from platelets.
    Anada Y; Igarashi Y; Kihara A
    Eur J Pharmacol; 2007 Jul; 568(1-3):106-11. PubMed ID: 17553484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral pharmacokinetic and pharmacodynamic effects of FTY720 in cats.
    Downes S; Chen YJ; Kyles A; Gregory C
    J Vet Pharmacol Ther; 2007 Feb; 30(1):55-61. PubMed ID: 17217402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
    O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
    Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.